Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Lassen KG, Lobritz MA, Bailey JR, Johnston S, Nguyen S, Lee B, Chou T, Siliciano RF, Markowitz M, Arts EJ.

PLoS Pathog. 2009 Apr;5(4):e1000377. doi: 10.1371/journal.ppat.1000377. Epub 2009 Apr 10.

2.

Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection.

Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN.

J Virol. 2011 Jan;85(2):979-86. doi: 10.1128/JVI.01721-10. Epub 2010 Nov 10.

3.

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN.

J Virol. 2014 Mar;88(6):3340-52. doi: 10.1128/JVI.03380-13. Epub 2014 Jan 3.

4.

CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.

Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG.

J Virol. 2013 Sep;87(17):9719-32. doi: 10.1128/JVI.01254-13. Epub 2013 Jul 3.

5.

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW.

J Virol. 2013 Mar;87(5):2401-11. doi: 10.1128/JVI.02964-12. Epub 2012 Dec 26.

6.

Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.

Chikere K, Webb NE, Chou T, Borm K, Sterjovski J, Gorry PR, Lee B.

Retrovirology. 2014 Jun 23;11:48. doi: 10.1186/1742-4690-11-48.

7.

Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.

Witwer KW, Watson AK, Blankson JN, Clements JE.

Retrovirology. 2012 Jan 12;9:5. doi: 10.1186/1742-4690-9-5.

8.

CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors.

O'Connell KA, Rabi SA, Siliciano RF, Blankson JN.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E689-98. doi: 10.1073/pnas.1108866108. Epub 2011 Aug 22.

9.

The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.

Rossi F, Querido B, Nimmagadda M, Cocklin S, Navas-Martín S, Martín-García J.

Retrovirology. 2008 Oct 6;5:89. doi: 10.1186/1742-4690-5-89.

10.

Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.

Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW.

J Virol. 2011 Sep;85(17):8514-27. doi: 10.1128/JVI.00736-11. Epub 2011 Jun 29.

11.

Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.

Wade J, Sterjovski J, Gray L, Roche M, Chiavaroli L, Ellett A, Jakobsen MR, Cowley D, Pereira Cda F, Saksena N, Wang B, Purcell DF, Karlsson I, Fenyö EM, Churchill M, Gorry PR.

Virology. 2010 Jan 20;396(2):246-55. doi: 10.1016/j.virol.2009.10.029. Epub 2009 Nov 13.

12.

Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.

Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E.

J Virol. 2010 Apr;84(8):4100-4. doi: 10.1128/JVI.02068-09. Epub 2010 Feb 10.

13.

Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

Julg B, Pereyra F, Buzón MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD.

Clin Infect Dis. 2010 Jul 15;51(2):233-8. doi: 10.1086/653677.

14.

Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.

Curriu M, Fausther-Bovendo H, Pernas M, Massanella M, Carrillo J, Cabrera C, López-Galíndez C, Clotet B, Debré P, Vieillard V, Blanco J.

PLoS One. 2012;7(2):e30330. doi: 10.1371/journal.pone.0030330. Epub 2012 Feb 1.

15.

A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B.

J Virol. 2009 Nov;83(21):11016-26. doi: 10.1128/JVI.01242-09. Epub 2009 Aug 19.

16.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

17.

Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.

Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, Bell JE, Wolinsky SM, Gabuzda D.

Virology. 2007 Mar 30;360(1):105-19. Epub 2006 Nov 7.

18.

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.

Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR.

Retrovirology. 2013 Sep 16;10:98. doi: 10.1186/1742-4690-10-98.

19.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

20.

Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages.

Walker-Sperling VE, Buckheit RW 3rd, Blankson JN.

J Virol. 2014 Sep 1;88(17):9789-98. doi: 10.1128/JVI.00860-14. Epub 2014 Jun 18.

Items per page

Supplemental Content

Write to the Help Desk